Key Insights

Highlights

Success Rate

83% trial completion

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 29/100

Termination Rate

6.7%

1 terminated out of 15 trials

Success Rate

83.3%

-3.2% vs benchmark

Late-Stage Pipeline

33%

5 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed with results

Key Signals

2 with results83% success

Data Visualizations

Phase Distribution

10Total
Not Applicable (3)
P 1 (1)
P 2 (1)
P 3 (1)
P 4 (4)

Trial Status

Completed5
Recruiting4
Not Yet Recruiting2
Active Not Recruiting2
Terminated1
Enrolling By Invitation1

Trial Success Rate

83.3%

Benchmark: 86.5%

Based on 5 completed trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT00571389Recruiting

A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.

NCT00339911Enrolling By InvitationPrimary

Collection and Distribution of Samples From Healthy Donors for In Vitro Research at the NCI-Frederick

NCT05141383Not ApplicableCompleted

Comparative Study of Diagnostic and Prognosis Biomarkers of Prostate Cancer in Liquid Biopsy (HOPE)

NCT06710262Completed

T-TAS® wS Method Comparison

NCT06834451Phase 4Active Not Recruiting

Bioequivalence Study of Revolade® Eltrombopag 50 mg

NCT06905847Phase 1CompletedPrimary

Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Primary Efficacy of HSK39004 Suspension for Inhalation

NCT06834503Phase 4Not Yet Recruiting

Bioequivalence Study of Clonazepam 2 Mg Tablets

NCT06861842Phase 4Active Not Recruiting

Bioequivalence Study of Lithium Carbonate 300 mg Tablets. Actilitio® in Healthy Subjects

NCT06842407RecruitingPrimary

Novel Targets for the Development of Monoclonal Antibodies for Immunotherapy)

NCT06823362Phase 4Not Yet Recruiting

Bioequivalence Study of Pentoxifylline 400 Mg in Healthy Subjects Under Fasting and Fed Conditions

NCT06738329Not ApplicableRecruiting

Investigating the Impact of the Seaweed Derived Food Additive, Carrageenan, on the Human Gut Microbiome

NCT06727383Not ApplicableRecruitingPrimary

CAR-NK Cells Production and Expansion From Patients With Lympho or Myeloproliferative Disorders and From Healthy Donors

NCT04762875Phase 2Terminated

MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies

NCT02124382Completed

Living Donor Liver Transplantation in Children

NCT00686205Phase 3CompletedPrimary

Evaluation of a Human Immunodeficiency Virus (HIV) Blood Screening Assay

Showing all 15 trials

Research Network

Activity Timeline